PT  - JOURNAL ARTICLE
AU  - Sampath, Deepak
AU  - Discafani, Carolyn M.
AU  - Loganzo, Frank
AU  - Beyer, Carl
AU  - Liu, Hao
AU  - Tan, Xingzhi
AU  - Musto, Sylvia
AU  - Annable, Tami
AU  - Gallagher, Patricia
AU  - Rios, Carol
AU  - Greenberger, Lee M.
TI  - MAC-321, a novel taxane with greater efficacy than paclitaxel and docetaxel <em>in vitro</em> and <em>in vivo</em>
DP  - 2003 Sep 01
TA  - Molecular Cancer Therapeutics
PG  - 873--884
VI  - 2
IP  - 9
4099  - http://mct.aacrjournals.org/content/2/9/873.short
4100  - http://mct.aacrjournals.org/content/2/9/873.full
SO  - Mol Cancer Ther2003 Sep 01; 2
AB  - The taxanes, paclitaxel (PTX) and docetaxel (DTX), belong to a novel class of anticancer drugs that stabilize microtubules and lead to tumor cell death. While both agents are widely used for the treatment of lung, breast, and ovarian cancer, many tumor types are refractory or develop resistance to these drugs. We describe here a novel analogue of DTX, designated MAC-321 [Microtubule/Apoptosis/Cytotoxic: 5β, 20-epoxy-1, 2α-, 4-, 7β-, 10β-, 13α-hexahydroxytax-11-en-9-one 4 acetate 2 benzoate 7-propionate 13-ester with (2R,3S)-N-tertbutoxycarbonyl-3-(2-furyl)isoserine], that overcomes P-glycoprotein-mediated resistance to PTX and DTX in preclinical model systems. Similar to PTX or DTX, MAC-321 enhanced the rate of tubulin polymerization in vitro and caused the bundling of microtubules in cells. MAC-321 inhibited proliferation of a panel of 14 tumor cell lines with minimal variation in potency (IC50 = 2.2 ± 1.4 nm; range = 0.6–5.3 nm). Unlike PTX or DTX, the IC50 of MAC-321 did not vary in cells that expressed low to moderate levels of P-glycoprotein. Even under extraordinary conditions in KB-V1 cells, which highly overexpress P-glycoprotein, resistance to MAC-321 was 80-fold compared with that of PTX (1400-fold) and DTX (670-fold). In addition, equivalent or less resistance to MAC-321 compared with PTX or DTX was observed in four cell lines that contain distinct point mutations within the taxane-binding site of β-tubulin. Most importantly, MAC-321 displayed superior in vivo efficacy because: (a) MAC-321 either partially or completely inhibited tumor growth in three tumor models that overexpressed P-glycoprotein and were resistant to PTX; and (b) unlike PTX or DTX, MAC-321 was highly effective when given orally. MAC-321 was also highly effective when given as single i.v. dose. Our findings suggest that MAC-321, which is currently under clinical evaluation, may have broad therapeutic value.